Dhp Korea Co., Ltd.

Quick facts

Phase 2 pipeline

• AT01 · Diabetes
  AT01 is a small molecule that targets the SGLT2 receptor.
• AT02 · Diabetes
  AT02 is a small molecule that targets the SGLT2 receptor.
• AT03
  AT03 is a small molecule that targets the [unknown] mechanism.
• AT04
  AT04 is an investigational drug with unknown mechanism of action.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Dhp Korea Co., Ltd. portfolio CI brief
• Dhp Korea Co., Ltd. pipeline updates RSS